1. Introduction {#sec1-cancers-11-01150}
===============

Cancer, a main public health issue is the leading cause of death globally. It was estimated that there will be about 18.1 million new cases of cancer and 9.6 million cancer deaths in 2018 \[[@B1-cancers-11-01150]\]. Thus, the etiology and pathogenesis of cancer has not been elucidated completely and their understanding is decisive. Genome-wide association studies (GWAS) have simplified the search for potential genetic variants that are implicated in many diseases including cancer and single nucleotide polymorphisms (SNPs) are well studied genetic variations found in human genome. The number of SNPs that have so far been identified to play an important role in cancer susceptibility is significant \[[@B2-cancers-11-01150]\]. It has been proposed that the immune system plays a key role in resisting and eliminating cancer cells and can affect cancer susceptibility. One of the main hallmarks of cancer cells is the immune suppression and evasion \[[@B3-cancers-11-01150]\].

Tumor cells express the programmed death-1-ligand 1 (PD-L1) as an adaptive, resistant mechanism to suppress the inhibitory receptor, namely programmed cell death-1 (PD-1) in order to evade host immunosurveillance \[[@B4-cancers-11-01150]\]. PD-1, also known as PD1 and CD279, is a cell surface immunosuppressive receptor belonging to immunoglobulin superfamily and is encoded by the *PDCD1* gene \[[@B5-cancers-11-01150],[@B6-cancers-11-01150],[@B7-cancers-11-01150]\]. PD-1, is a negative regulator of the immune system and is expressed on CD4+ T cells, CD8+ T cells, NKT cells, B cells, and monocytes \[[@B8-cancers-11-01150],[@B9-cancers-11-01150]\]. The antitumor CD8+ T cells exhibit preferential expression of PD-1 leading to their exhaustion and functional impairment, which in turns lead to attenuated tumor-specific immunity disseminating tumor progression \[[@B10-cancers-11-01150],[@B11-cancers-11-01150]\]. The PD-1 blockade elevates the magnitude of T cell response such as proliferation of T cells and production of effector cytokines \[[@B12-cancers-11-01150]\]. Additionally, PD-L1 signaling through conserved sequence motifs confers resistance of cancer cells towards proapoptotic interferon (IFN)-mediated cytotoxicity \[[@B13-cancers-11-01150]\].

PD-1/PD-L1 axis is an important pathway to maintain immune tolerance and prevent autoimmune diseases in the evolution of immunity \[[@B14-cancers-11-01150],[@B15-cancers-11-01150],[@B16-cancers-11-01150]\]. Furthermore, it influences the balance between tumor immune surveillance and immune resistance \[[@B17-cancers-11-01150],[@B18-cancers-11-01150]\]. Elevated PD-L1 expression in tumor cells or tumor-infiltrating lymphocytes (TILs) leads to the exhaustion of T cells \[[@B19-cancers-11-01150]\], and hence attenuated tumor-specific immunity disseminating tumor progression \[[@B20-cancers-11-01150]\]. Gene polymorphisms might affect the normal process of gene activation and transcriptional initiation, hence influence the quantity of mRNA and encoded protein \[[@B21-cancers-11-01150]\]. Both *PD-1* and *PD-L1* are polymorphic. Several studies investigated the association between genetic polymorphisms of *PD-1* and *PD-L1* genes and the risk of various cancers, but the finding are still inconclusive \[[@B5-cancers-11-01150],[@B6-cancers-11-01150],[@B7-cancers-11-01150],[@B22-cancers-11-01150],[@B23-cancers-11-01150],[@B24-cancers-11-01150],[@B25-cancers-11-01150],[@B26-cancers-11-01150],[@B27-cancers-11-01150],[@B28-cancers-11-01150],[@B29-cancers-11-01150],[@B30-cancers-11-01150],[@B31-cancers-11-01150],[@B32-cancers-11-01150],[@B33-cancers-11-01150],[@B34-cancers-11-01150],[@B35-cancers-11-01150],[@B36-cancers-11-01150],[@B37-cancers-11-01150],[@B38-cancers-11-01150],[@B39-cancers-11-01150],[@B40-cancers-11-01150],[@B41-cancers-11-01150],[@B42-cancers-11-01150],[@B43-cancers-11-01150],[@B44-cancers-11-01150],[@B45-cancers-11-01150],[@B46-cancers-11-01150],[@B47-cancers-11-01150],[@B48-cancers-11-01150],[@B49-cancers-11-01150],[@B50-cancers-11-01150],[@B51-cancers-11-01150],[@B52-cancers-11-01150]\]. Thus, we performed a comprehensive meta-analysis in order to study the association of polymorphisms in *PD-1* (rs2227981, rs2227982, rs11568821, rs7421861, rs36084323, and rs10204525) and *PD-L1* (rs4143815, and rs2890658) with the risk of cancer. The locations and base pair positions of single nucleotide polymorphisms (SNPs) in *PD-1* and *PD-L1* genes are presented in [Table 1](#cancers-11-01150-t001){ref-type="table"}.

2. Results {#sec2-cancers-11-01150}
==========

2.1. Study Characteristics {#sec2dot1-cancers-11-01150}
--------------------------

A flow diagram of the study selection process is shown in [Figure 1](#cancers-11-01150-f001){ref-type="fig"}. For *PD-1* polymorphisms, 54 case-control studies from a total of 26 articles \[[@B5-cancers-11-01150],[@B6-cancers-11-01150],[@B7-cancers-11-01150],[@B22-cancers-11-01150],[@B23-cancers-11-01150],[@B24-cancers-11-01150],[@B25-cancers-11-01150],[@B26-cancers-11-01150],[@B27-cancers-11-01150],[@B28-cancers-11-01150],[@B29-cancers-11-01150],[@B30-cancers-11-01150],[@B31-cancers-11-01150],[@B32-cancers-11-01150],[@B33-cancers-11-01150],[@B34-cancers-11-01150],[@B35-cancers-11-01150],[@B36-cancers-11-01150],[@B37-cancers-11-01150],[@B38-cancers-11-01150],[@B39-cancers-11-01150],[@B40-cancers-11-01150],[@B41-cancers-11-01150],[@B42-cancers-11-01150],[@B43-cancers-11-01150],[@B52-cancers-11-01150]\] examining the associations of 6 widely studied polymorphisms in *PD-1* gene and cancer risk were included in this meta-analysis. There were 16 studies involving 5622 cases and 5450 controls that reported the association between *PD-1* rs2227981 polymorphism and cancer. Eleven studies including 4766 cases and 5839 controls investigated the relationship between *PD-1* rs2227982 polymorphism and cancer. Nine studies with 1846 cases and 1907 cases reported the association between *PD-1* rs11568821 variant and cancer risk. Seven studies including 3576 cancer cases and 5277 controls studied the correlation between *PD-1* rs7421861 polymorphism and cancer. Seven studies involving 3589 cases and 4314 controls examined the association between *PD-1* rs36084323 polymorphism and cancer risk. Six studies including 3366 cancer cases and 4391 controls studied the relationship between *PD-1* rs10204525 polymorphism and cancer.

For *PD-L1* polymorphisms, 13 case-control studies from 10 articles \[[@B27-cancers-11-01150],[@B38-cancers-11-01150],[@B44-cancers-11-01150],[@B45-cancers-11-01150],[@B46-cancers-11-01150],[@B47-cancers-11-01150],[@B48-cancers-11-01150],[@B49-cancers-11-01150],[@B50-cancers-11-01150],[@B51-cancers-11-01150]\] that assessed the impact of two polymorphisms of *PD-L1* were included in the pooled analysis. Eight studies including 3030 cases and 4145 controls evaluated the association between *PD-L1* rs4143815 polymorphism and cancer risk. Five studies with 1909 cases and 1970 controls assessed the correlation between *PD-L1* rs2890658 variant and cancer risk. The characteristics of all these studies are shown in [Table 2](#cancers-11-01150-t002){ref-type="table"}.

2.2. Main Analysis Results {#sec2dot2-cancers-11-01150}
--------------------------

### 2.2.1. Association of *PD-1* Polymorphisms with Cancer Risk {#sec2dot2dot1-cancers-11-01150}

The pooled analysis involving *PD-1* rs2227981 polymorphism revealed that this variant significantly decreased the overall cancer risk in recessive (OR = 0.82, 95% CI = 0.68--0.99, *p* = 0.04, TT vs. CT+CC) genetic models ([Table 3](#cancers-11-01150-t003){ref-type="table"} and [Figure 2](#cancers-11-01150-f002){ref-type="fig"}).

In regard to *PD-1* rs11568821 polymorphism, the findings indicated that this variant significantly decreased the overall cancer risk in heterozygous (OR = 0.79, 95% CI = 0.67--0.94, *p* = 0.006, AG vs. GG) and dominant (OR = 0.82, 95% CI = 0.70--0.96, *p* = 0.020, AG+AA vs. GG) genetic models ([Table 3](#cancers-11-01150-t003){ref-type="table"}).

The pooled analysis proposed that *PD-1* rs7421861 polymorphism significantly increased the risk of overall cancer in heterozygous (OR = 1.16, 95% CI = 1.02--1.33, *p* = 0.03, CT vs. TT) genetic models ([Table 3](#cancers-11-01150-t003){ref-type="table"}).

No significant association was found between *PD-1* rs2227982, rs36084323, and rs10204525 polymorphisms and cancer susceptibility ([Table 3](#cancers-11-01150-t003){ref-type="table"}).

We performed stratified analyses and the findings are summarized in [Table 4](#cancers-11-01150-t004){ref-type="table"}. We observed that *PD-1* rs2227981 significantly decreased the risk of gastrointestinal (GI) cancer (OR = 0.68, 95% CI = 0.56--0.84, *p* = 0.000, TT vs. CC; OR = 0.60, 95% CI = 0.40--0.89, *p* = 0.011, TT vs. CT+CC; OR = 0.83, 95% CI = 0.75--0.91, *p* = 0.000, T vs. C), lung cancer (OR = 0.65, 95% CI = 0.44--0.97, *p* = 0.030, TT vs. CC; OR = 0.84, 95% CI = 0.71--0.99, *p* = 0.043, CT+TT vs. CC; OR = 0.83, 95% CI = 0.72--0.95, *p* = 0.009, T vs. C), and breast cancer (OR = 0.82, 95% CI = 0.70--0.06, *p* = 0.012, T vs. C).

Furthermore, we found that the *PD-1* rs2227982 was associated with an increased risk of cancer in hospital based studies (OR = 1.22, 95% CI = 1.06--1.40, *p* = 0.006, CT vs. CC; OR = 1.20, 95% CI = 1.05--1.37, *p* = 0.008, CT+TT vs. CC). We also found a negative correlation between the *PD-1* rs2227982 polymorphism and the risk of gastrointestinal cancer (OR = 1.18, 95% CI = 1.04--1.34, *p* = 0.011, CT vs. CC; OR = 1.16 (95% CI = 1.03--1.30, *p* = 0.017, CT+TT vs. CC) and breast cancer risk (OR = 0.73, 95% CI = 0.59--0.90, *p* = 0.004, CT vs. CC; OR = 0.73, 95% CI = 0.57--0.93, *p* = 0.010, TT vs. CC; OR = 73, 95% CI = 0.60--0.89, *p* = 0.002, CT+TT vs. CC; OR = 0.85, 95% CI = 76--0.96, *p* = 0.010, T vs. C). With reference to the *PD-1* rs7421861, our finding proposed that this variant significantly increased the risk of cancer in hospital based studies (OR = 1.89, 95% CI = 1.01--1.40, *p* = 0.042, CT vs. TT) as well as gastrointestinal cancer (OR = 1.19, 95% CI = 1.01--1.40, *p* = 0.042, CT vs. CC). Moreover, a significantly reduce cancer risk in population-based studies (OR = 0.80, 95% CI = 0.66--0.97, *p* = 0.020, AG vs. GG) was observed regarding *PD-1* rs11568821 variant. The *PD-1* rs36084323 variant was however associated with an increased risk of cancer in hospital-based studies (OR = 1.17, 95% CI = 1.01--1.35, *p* = 0.042, AG+AA vs. GG).

### 2.2.2. *PD-L1* Polymorphisms and Cancer Risk {#sec2dot2dot2-cancers-11-01150}

The pooled ORs results for the relationship between the *PD-L1* rs4143815 and rs2890658 polymorphisms and the risk of cancer are shown in [Table 3](#cancers-11-01150-t003){ref-type="table"}. The *PD-L1* rs4143815 variant significantly decreased the risk of cancer in homozygous (OR = 0.62, 95% CI = 0.41--0.94, *p* = 0.02), dominant (OR = 0.70, 95% CI = 0.50--0.97, *p* = 0.03), recessive (OR = 0.76, 95% CI = 0.60--0.96, *p* = 0.02), and allele (OR = 0.78, 95% CI = 0.63--0.96, *p* = 0.02) genetic models ([Table 3](#cancers-11-01150-t003){ref-type="table"} and [Figure 3](#cancers-11-01150-f003){ref-type="fig"}). The pooled analysis did not support an association between *PD-L1* rs2890658 polymorphism and risk of cancer susceptibility ([Table 3](#cancers-11-01150-t003){ref-type="table"}).

We did stratified analysis ([Table 4](#cancers-11-01150-t004){ref-type="table"}) and the findings revealed that *PD-L1* rs4143815 polymorphism significantly reduced the risk of gastrointestinal cancer (OR = 0.68, 95% CI = 0.48--0.97, *p* = 0.032, CC vs. GG; OR = 0.59, 95% CI = 0.37--0.96, *p* = 0.033, CC vs. GG; OR = 0.64, 95% CI = 0.43--0.95, *p* = 0.028, CG+CC vs. GG; OR = 0.76, 95% CI = 0.59--0.98, *p* = 0.034, C vs. G) and hospital-based studies (OR = 0.75, 95% CI = 0.58--0.97, *p* = 0.030, CC vs. CG+GG; OR = 0.76, 95% CI = 0.58--0.99, *p* = 0.043, C vs. G). In regard to *PD-L1* rs2890658, a positive correlation between this variant and the risk of lung cancer (OR = 1.74, 95% CI = 1.37--2.19, *p* = 0.000, AC vs. AA; OR = 1.77, 95% CI = 1.41--2.23, *p* = 0.000, AC+CC vs. AA; OR = 1.72, 95% CI = 1.39--2.13, *p* = 0.000 C vs. A) was observed ([Table 4](#cancers-11-01150-t004){ref-type="table"}).

2.3. Heterogeneity {#sec2dot3-cancers-11-01150}
------------------

As shown in [Table 3](#cancers-11-01150-t003){ref-type="table"}, heterogeneity between the studies regarding the *PD-1* rs2227981, *PD-1* rs36084323, *PD-1* rs10204525, and *PD-L1* rs4143815 was observed in all genetic models. For *PD-1* rs2227982 polymorphism, our results showed no evidence of heterogeneity in the recessive model (TT vs. CT+CC). Regarding *PD-1* rs11568821, heterogeneity was not observed in the heterozygous, homozygous, dominant, and recessive genetic models. Similarly, no evidence of heterogeneity in the heterozygous, homozygous, and recessive genetic models of *PD-1* rs7421861 was found. Heterogeneity was not detected in the homozygous and recessive genetic models of the *PD-L1* rs2890658.

2.4. Publication Bias {#sec2dot4-cancers-11-01150}
---------------------

The potential publication bias of the studies included in the present meta-analysis was examined by Begg's funnel plot and Egger's test. The results of publication bias are summarized in [Table 3](#cancers-11-01150-t003){ref-type="table"}. Based on the above analysis, no publication bias for the association of *PD-1* rs2227982, *PD-1* rs7421861, and *PD-L1* rs4143815 variants in all genetic models and cancer risk was demonstrated ([Table 3](#cancers-11-01150-t003){ref-type="table"} and [Figure 4](#cancers-11-01150-f004){ref-type="fig"}).

As presented in [Table 3](#cancers-11-01150-t003){ref-type="table"} and [Figure 5](#cancers-11-01150-f005){ref-type="fig"}, no publication bias was observed in recessive genetic model of *PD-1* rs2227981. Obvious publication bias was not found in the heterozygous, dominant, and allele genetic models of the *PD-1* rs11568821 *and PD-L1* rs2890658 ([Table 3](#cancers-11-01150-t003){ref-type="table"}). Moreover, the publication bias was not observed in heterozygous, dominant, recessive, and allele genetic models of the *PD-1* rs36084323 and *PD-1* rs10204525. ([Table 3](#cancers-11-01150-t003){ref-type="table"}).

2.5. Sensitivity Analysis {#sec2dot5-cancers-11-01150}
-------------------------

Sensitivity analysis was conducted by replicating analysis after neglecting one study at a time to estimate the effect of quality of studies on the final findings. Taken together, our findings from the meta-analysis of the correlation between analyzed polymorphisms and cancer susceptibility remained unchanged in the heterozygous (*PD-1* rs2227982, *PD-1* rs36084323 and *PD-1* rs10204525), homozygous (*PD-1* rs2227982, *PD-1* rs7421861, *PD-1* rs36084323, *PD-1* rs10204525 and *PD-L1* rs2890658), dominant (*PD-1* rs36084323 and *PD-1* rs10204525), recessive (*PD-1* rs2227982, *PD-1* rs7421861, *PD-1* rs36084323 and *PD-L1* rs2890658), and allele (*PD-1* rs2227982, *PD-1* rs7421861 *PD-1* rs10204525 and *PD-L1* rs2890658) genetic models ([Figure 6](#cancers-11-01150-f006){ref-type="fig"}). In regard to *PD-L1* rs4143815, the findings changed in the heterozygous, homozygous, dominant, recessive, and allele genetics models ([Figure 7](#cancers-11-01150-f007){ref-type="fig"}).

3. Discussion {#sec3-cancers-11-01150}
=============

It has been proposed that environmental and genetic factors contribute to cancer development \[[@B53-cancers-11-01150],[@B54-cancers-11-01150]\]. Single nucleotide polymorphisms (SNPs) can be considered as biological markers that help scientists to recognize genes that are related to cancer \[[@B55-cancers-11-01150]\].

PD-1 and PD-L1 are involved in the regulation of programmed cell death, which is the regulator of cancer cell proliferation as well as primary response in many cancer therapy strategies. Several studies have investigated the association between *PD-1* as well as *PD-L1* polymorphisms and the risk of various types of cancers; however, the findings remain discrepant. This meta-analysis provides, for the first time a quantitative estimated of the association between six SNPs of *PD-1* and two SNPs of *PD-L1* gene and cancer susceptibility. The findings indicated that *PD-1* rs2227981 and rs11568821 polymorphisms as well as *PDL-1* rs4143815 variant significantly decreased the overall cancer risk, while *PD-1* rs7421861 polymorphism significantly increased the risk of overall cancer. Our findings revealed no significant association between *PD-1* rs2227982, *PD-1* rs36084323, PD-1 rs10204525, and *PD-L1* rs2890658 polymorphisms and overall cancer risk.

We performed stratified analyses and our findings indicate that *PD-1* rs2227981 significantly decreased the risk of gastrointestinal cancer, lung cancer and breast cancer. The *PD-1* rs2227982 was associated with increased risk of cancer in hospital-based studies and lower risk of gastrointestinal and breast cancer. Similarly to *PD-1* rs7421861, the *PD-1* rs7421861 and *PD-1* rs36084323 variants significantly increased the risk of cancer in hospital-based studies. The *PD-1* rs11568821 was linked to reduce risk of cancer in population-based studies. Moreover, our findings revealed that *PD-L1* rs4143815 polymorphism significantly reduced the risk of gastrointestinal cancer and hospital-based studies. A positive correlation between *PD-L1* rs2890658 variant and the risk of lung cancer was observed.

Recently, Zou et al. \[[@B56-cancers-11-01150]\] performed a meta-analysis of the association between *PD-L1* rs4143815 polymorphism and the risk of cancer and found also a significant association between this variant and cancer risk, which is in line with our findings. Like our results, a meta-analysis conducted by Da et al. \[[@B57-cancers-11-01150]\] revealed no significant association between *PD-1* rs36084323 polymorphism and overall cancer susceptibility. Similar to previous meta-analysis conducted by Zhang et al. \[[@B58-cancers-11-01150]\], we have also found that *PD-1* rs2227981 and rs11568821 polymorphisms were associated with decreased cancer susceptibility. In another study, Dong et al. \[[@B59-cancers-11-01150]\] conducted a meta-analysis aimed to inspect the associations between *PD-1* rs2227981, rs2227982, rs7421861, and rs11568821 polymorphisms and cancer risk. There were seven studies involving 3395 cases and 2912 controls for *PD-1* rs2227981, four studies including 1961 cases and 2390 controls for *PD-1* rs2227982, four studies with 1975 cases and 2403 controls for *PD-1* rs7421861, and four studies for PD-1 rs11568821 variant and cancer risk. They have found that rs2227981 and rs11568821 polymorphisms significantly decreased the risk of cancer. Mamat et al. \[[@B60-cancers-11-01150]\] conducted a meta-analysis of six studies involving 1427 cases and 1811 controls and have observed no significant association between *PD-1* rs2227981 polymorphism and the risk of cancer.

Nevertheless, the number of cases and controls as well as the number of polymorphisms in our meta-analysis is higher than in those previously published meta-analysis studies.

It has been proposed that gene expression could be potentially affected by genetic polymorphisms \[[@B21-cancers-11-01150],[@B61-cancers-11-01150],[@B62-cancers-11-01150],[@B63-cancers-11-01150]\]. Alterations in the expression of PD-1 and PDL-1 were detected in many cancer types including gastric cancer, lung cancer, thyroid cancer, laryngeal carcinoma, extrapulmonary small cell carcinoma, and breast cancer \[[@B63-cancers-11-01150],[@B64-cancers-11-01150],[@B65-cancers-11-01150],[@B66-cancers-11-01150],[@B67-cancers-11-01150],[@B68-cancers-11-01150],[@B69-cancers-11-01150]\].

PD-1/PD-L1 axis impairs T cell activation by preventing Ras-Raf-MEK-ERK and PI3K-AKT signaling pathways, which are mainly believed to promote proliferation and differentiation of T cell \[[@B70-cancers-11-01150]\]. The inhibitory regulation of PD-1/PD-L1 is typically compared to a brake in T cell activation \[[@B71-cancers-11-01150]\]. PD-L1 is exerted by tumors to escape from immune system. Tumor-specific PD-L1-expression was not prognostic in colorectal cancer, while high immune cell-specific PD-1 expression was associated with a prolonged overall survival \[[@B72-cancers-11-01150]\]. It has been revealed that high expression of PD-1 on peripheral blood T cell subsets is correlated with poor prognosis of metastatic gastric cancer \[[@B73-cancers-11-01150]\]. Fang et al. \[[@B74-cancers-11-01150]\] reported that the peripheral blood PD-1 expression was significantly higher in breast cancer patients than benign breast tumors. PD-1 and PD-L1 expression have been shown to be associated with adverse clinicopathological features in clear cell renal carcinoma \[[@B75-cancers-11-01150]\].

This meta-analysis has however several limitations. Firstly, there are relatively small sample sizes of studies for some polymorphisms that should be expanded. Secondly, we have included in this meta-analysis only studies published in English, thus publication bias may have occurred. Thirdly, obvious heterogeneities were found in certain polymorphisms. Differences in ethnic background, type of cancer, and other baseline characteristics of participants may contribute to between-study heterogeneities. Lastly, gene-gene and gene-environment interactions which may affect cancer susceptibility were not evaluated in this meta-analysis due to lack of sufficient data. Therefore, the results of this meta-analysis should be cautiously interpreted.

In conclusion, the current meta-analysis suggests that rs2227981 and rs11568821 polymorphisms of *PD-1* and the rs4143815 polymorphism of *PD-L1* were associated with protection against cancer, while *PD-1* rs7421861 polymorphism significantly increased cancer risk.

4. Methods {#sec4-cancers-11-01150}
==========

4.1. Literature Search {#sec4dot1-cancers-11-01150}
----------------------

We searched PubMed, Web of Science, Scopus, and Google Scholar databases for publications that studied the association between *PD-1* and *PD-L1* polymorphisms and cancer risk. The last search was updated on 18 December 2019. The following search terms were used; "programmed cell death 1 or *PDCD1* or *PD-1*, or *CD279*, or programmed death-1-ligand 1 or *CD274* or *B7-H1*" and "polymorphism or single nucleotide polymorphism or SNP or variation" and "cancer or carcinoma, or tumor".

The process of recognizing eligible studies is presented in [Figure 1](#cancers-11-01150-f001){ref-type="fig"}. The inclusion and exclusion criteria were as follows. (1) The studies evaluated the association between the *PD-1* and *PD-L1* polymorphisms and cancer risk, (2) studies with necessary information on genotype or allele frequencies to estimate ORs and 95% Cis, (3) studies with human subjects, and (4) case-control design. We excluded reviews, conference papers, and other studies that were published as abstracts only.

4.2. Data Extraction {#sec4dot2-cancers-11-01150}
--------------------

The data were recovered from eligible articles independently by two authors. Disagreements were discussed with the third investigator. The following information was recorded for each study: first author's name, publication year, patient's nationality, genotypes, and allele frequencies.

4.3. Statistical Analysis {#sec4dot3-cancers-11-01150}
-------------------------

We performed a meta-analysis to assess the association between *PD-1* and *PD-L1* polymorphisms and cancer susceptibility. The observed genotype frequencies in the controls were tested for Hardy-Weinberg equilibrium (HWE) using the chi-squared test.

Odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the association between *PD-1* and *PD-L1* polymorphisms and cancer risk in five genetic models, which were heterozygous, homozygous, dominant, recessive, and allele. The strength of the association between each polymorphism and cancer risk was assessed by pooled odds ratios (ORs) and their 95% confidence intervals (CIs). The Z-test was used for statistical significance of the pooled OR. We estimated the between-study heterogeneity by the Q-test and I2 test: If I2 \< 50% and *P* \> 0.1, the fixed effects model was used to estimate the ORs and the 95% CI; otherwise, the random effects model was applied.

We evaluated publication bias using funnel plots for visual inspection and conducting quantitative estimations with Egger's test.

Sensitivity analysis was achieved by excluding each study in turn to assess the stability of the results. All analyses were achieved by STATA 14.1 software (Stata Corporation, College Station, TX, USA).

5. Conclusions {#sec5-cancers-11-01150}
==============

The findings of our meta-analysis proposed that *PD-1* rs2227981, rs11568821, rs7421861, as well as *PD-L1* rs4143815 polymorphisms associated with overall cancer susceptibility. Further well-designed studies with large sample sizes are warranted to confirm our findings.

Andrzej Malecki was supported by Institute of Physiotherapy and Health Sciences, The Jerzy Kukuczka Academy of Physical Education in Katowice. Saeid Ghavami was supported by Research Manitoba New Investigators Operating Grant and CancerCare Manitoba Operating grant.

M.H. conceptualized and designed the study, conducted statistical analysis, and proofread the final draft. S.S., S.K., and A.M.-R. searched the literature, extracted the data, and prepared the figures. S.G. and E.W. conducted the final proofread, discussed the results, and prepared the final draft of manuscript. A.M. conducted the final proofread and provided information about cancer involvement. All authors reviewed the manuscript.

This research received no external funding.

The authors declare no conflicts of interest.

![Flow diagram of study selection for this meta-analysis.](cancers-11-01150-g001){#cancers-11-01150-f001}
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###### 

Locations and base pair positions of single nucleotide polymorphisms (SNPs) in *PD-1* and *PD-L1* genes.

  Gene Name   db SNP rs \# ID ^a^   Chromosome Position   Location   Base Change   Amino Acid Change
  ----------- --------------------- --------------------- ---------- ------------- -------------------
  *PD-1*      rs2227981             chr2:241851121        Upstream   C/T           \-
              rs2227982             chr2:241851281        Exon       C/T           Ala215Val
              rs7421861             chr2:241853198        Intron     T/C           \-
              rs11568821            chr2:241851760        Intron     G/A           \-
              rs36084323            chr2:241859444        Upstream   G/A           \-
              rs10204525            chr2:241850169        3′UTR      A/G           \-
  *PD-L1*     rs4143815             chr9:5468257          3′UTR      G/C           \-
              rs2890658             chr9:5465130          Intron     A/C           \-

^a^ db = databases; rs \# = reference SNP \#; UTR: untranslated region.

cancers-11-01150-t002_Table 2

###### 

Characteristics of the studies eligible for meta-analysis.

  First Author        Year   Country   Ethnicity        Cancer Type                                 Source of Control   Genotyping Method   Case/Control   Cases   Controls   HWE                                                  
  ------------------- ------ --------- ---------------- ------------------------------------------- ------------------- ------------------- -------------- ------- ---------- ----- ------ ------ ------ ----- ----- ------ ------ -------
  *PD-1* rs2227981                                                                                                                                         CC      CT         TT    C      T      CC     CT    TT    C      T      
  Fathi               2019   Iran      Asian            Squamous Cell Carcinomas of Head and Neck   HB                  PCR-RFLP            150/150        65      69         16    199    101    66     71    13    203    97     0.317
  Gomez               2018   Brazil    South American   Cutaneous Melanoma                          PB                  RT-PCR              250/250        87      126        37    300    200    85     130   35    300    200    0.188
  Haghshenas          2011   Iran      Asian            Breast cancer                               PB                  PCR-RFLP            435/328        194     191        50    579    291    137    145   46    419    237    0.446
  Haghshenas          2017   Iran      Asian            Thyroid cancer                              PB                  PCR-RFLP            105/160        40      51         14    131    79     99     51    10    249    71     0.331
  Hua                 2011   China     Asian            breast cancer                               PB                  PCR-RFLP            486/478        295     169        22    759    213    244    210   24    698    258    0.012
  Ivansson            2010   Sweden    Caucasian        Cervical cancer                             PB                  TaqMan              1300/810       471     603        226   1545   1055   257    375   178   889    731    0.064
  Li                  2016   China     Asian            Cervical cancer                             PB                  PCR-RFLP            256/250        45      167        44    257    255    62     101   87    225    275    0.004
  Li                  2017   China     Asian            Ovarian cancer                              HB                  PCR-LDR             620/620        351     233        36    935    305    319    250   51    888    352    0.837
  Ma                  2015   China     Asian            lung cancer                                 PB                  PCR-RFLP            528/600        244     216        68    704    352    256    246   98    758    442    0.004
  Mojtahedi           2012   Iran      Asian            Colon cancer                                PB                  PCR-RFLP            175/200        47      102        26    196    154    75     89    36    239    161    0.290
  Mojtahedi           2012   Iran      Asian            Rectal cancer                               PB                  PCR-RFLP            25/200         12      7          6     31     19     75     89    36    239    161    0.290
  Namavar Jahromi     2017   Iran      Asian            Malignant Brain tumor                       PB                  PCR-RFLP            56/150         22      31         3     75     37     94     47    9     235    65     0.346
  Pirdelkhosh         2018   Iran      Asian            NSCLC                                       PB                  PCR-RFLP            206/173        78      100        28    256    156    60     89    24    209    137    0.321
  Savabkar            2013   Iran      Asian            Gastric cancer                              HB                  PCR-RFLP            122/166        50      66         6     166    78     89     70    7     248    84     0.136
  Yin                 2014   China     Asian            Lung cancer                                 PB                  PCR                 324/330        198     106        20    502    146    181    105   44    467    193    0.001
  Zhou                2016   China     Asian            ESCC                                        PB                  PCR-LDR             584/585        291     241        52    823    345    310    229   46    849    321    0.683
  *PD-1* rs2227982                                                                                                                                         CC      CT         TT    C      T      CC     CT    TT    C      T      
  Fathi               2019   Iran      Asian            Squamous Cell Carcinomas of Head and Neck   HB                  PCR-RFLP            150/150        146     4          0     296    4      146    4     0     296    4      0.868
  Gomez               2018   Brazil    South American   Cutaneous Melanoma                          PB                  RT-PCR              250/250        227     21         2     475    25     225    25    0     475    25     0.405
  Hua                 2011   China     Asian            breast cancer                               PB                  PCR-RFLP            487/506        111     249        127   471    503    95     268   143   458    554    0.121
  Ma                  2015   China     Asian            lung cancer                                 PB                  PCR-RFLP            528/600        343     148        37    834    222    404    168   28    976    224    0.056
  Qiu                 2014   China     Asian            esophageal cancer                           HB                  PCR-LDR             616/681        159     303        154   621    611    189    325   167   703    659    0.245
  Ramzi               2018   Iran      Asian            Leukemia                                    PB                  PCR-RFLP            59/38          38      18         3     94     24     17     19    2     53     23     0.255
  Ren                 2016   China     Asian            Breast Cancer                               PB                  MassARRAY           557/582        172     257        128   601    513    137    299   146   573    591    0.503
  Tan                 2018   China     Asian            Ovarian cancer                              PB                  PCR-RFLP            164/170        87      60         17    234    94     111    48    11    270    70     0.075
  Tang                2015   China     Asian            Gastric cardia adenocarcinoma               HB                  PCR-LDR             330/603        75      168        87    318    342    163    292   148   618    588    0.448
  Tang                2017   China     Asian            Esophagogastric junction adenocarcinoma     HB                  SNPscan             1041/1674      220     549        272   989    1093   416    816   442   1648   1700   0.309
  Zhou                2016   China     Asian            ESCC                                        PB                  PCR-LDR             584/585        149     305        130   603    565    150    297   138   597    573    0.702
  *PD-1* rs7421861                                                                                                                                         TT      TC         CC    T      C      TT     TC    CC    T      C      
  Ge                  2015   China     Asian            Colon cancer                                HB                  PCR-RFLP            199/620        133     60         6     326    72     440    163   17    1043   197    0.685
  Ge                  2015   China     Asian            Rectal cancer                               HB                  PCR-RFLP            362/620        241     114        7     596    128    440    163   17    1043   197    0.685
  Hua                 2011   China     Asian            Breast cancer                               PB                  PCR-RFLP            490/512        333     146        11    812    168    370    130   12    870    154    0.885
  Qiu                 2014   China     Asian            esophageal cancer                           HB                  PCR-LDR             600/673        411     168        21    990    210    460    188   25    1108   238    0.295
  Ren                 2016   China     Asian            Breast Cancer                               PB                  MassARRAY           560/580        341     196        23    878    242    347    205   28    899    261    0.746
  Tang                2015   China     Asian            Gastric cardia adenocarcinoma               HB                  PCR-LDR             324/598        226     91         7     543    105    408    168   22    984    212    0.368
  Tang                2017   China     Asian            esophagogastric junction adenocarcinoma     HB                  SNPscan             1041/1674      642     358        41    1642   440    1166   454   54    2786   562    0.232
  *PD-1* rs11568821                                                                                                                                        GG      AG         AA    G      A      GG     AG    AA    G      A      
  Bayram              2012   Turkey    Asian            liver cancer                                HB                  PCR-RFLP            236/236        191     45         0     427    45     180    56    0     416    56     0.039
  Fathi               2019   Iran      Asian            Squamous Cell Carcinomas of Head and Neck   HB                  PCR-RFLP            150/150        119     27         4     265    35     113    32    5     258    42     0.162
  Haghshenas          2011   Iran      Asian            Breast cancer                               PB                  PCR-RFLP            436/290        365     63         8     793    79     231    55    4     517    63     0.726
  Haghshenas          2017   Iran      Asian            Thyroid cancer                              PB                  PCR-RFLP            95/160         82      13         0     177    13     127    30    3     284    36     0.440
  Ma                  2015   China     Asian            lung cancer                                 PB                  PCR-RFLP            528/600        426     102        0     954    102    456    142   2     1054   146    0.009
  Namavar Jahromi     2017   Iran      Asian            Malignant Brain tumor                       PB                  PCR-RFLP            56/150         47      8          1     102    10     116    30    4     262    38     0.240
  Pirdelkhosh         2018   Iran      Asian            NSCLC                                       PB                  PCR-RFLP            206/173        171     31         4     373    39     144    26    3     314    32     0.168
  Ramzi               2018   Iran      Asian            Leukemia                                    PB                  PCR-RFLP            59/38          38      18         3     94     24     21     13    4     55     21     0.373
  Yousefi             2013             Asian            colon cancer                                PB                                      80/110         18      27         35    63     97     43     45    22    131    89     0.114
  *PD-1* rs36084323                                                                                                                                        GG      AG         AA    G      A      GG     AG    AA    G      A      
  Gomez               2018   Brazil    South American   Cutaneous Melanoma                          PB                  RT-PCR              250/250        226     18         6     470    30     225    25    0     475    25     0.405
  Hua                 2011   China     Asian            Breast cancer                               PB                  PCR-RFLP            490/512        103     271        116   477    503    140    260   112   540    484    0.673
  Li                  2017   China     Asian            Ovarian cancer                              HB                  PCR-LDR             620/620        150     301        169   601    639    168    323   129   659    581    0.251
  Ma                  2015   China     Asian            lung cancer                                 PB                  PCR-RFLP            528/600        144     246        138   534    522    156    296   148   608    592    0.747
  Shamsdin            2018   Iran      Asian            Colon cancer                                PB                  PCR-RFLP            76/73          60      15         1     135    17     18     28    27    64     82     0.059
  Tang                2017   China     Asian            esophagogastric junction adenocarcinoma     HB                  SNPscan             1041/1674      238     521        282   997    1085   430    800   444   1660   1688   0.071
  Zhou                2016   China     Asian            ESCC                                        PB                  PCR-LDR             584/585        147     303        134   597    571    145    298   142   588    582    0.649
  *PD-1* rs10204525                                                                                                                                        AA      AG         GG    A      G      AA     AG    GG    A      G      
  Li                  2013   China     Asian            HCC                                         PB                  TIANamp             271/318        180     83         8     443    99     160    130   28    450    186    0.828
  Qiu                 2014   China     Asian            esophageal cancer                           HB                  PCR-LDR             600/651        317     240        43    874    326    345    243   63    933    369    0.039
  Ren                 2016   China     Asian            Breast Cancer                               PB                  MassARRAY           559/582        257     248        54    762    356    291    240   51    822    342    0.880
  Tang                2015   China     Asian            Gastric cardia adenocarcinoma               HB                  PCR-LDR             313/581        169     123        21    461    165    309    219   53    837    325    0.120
  Tang                2017   China     Asian            esophagogastric junction adenocarcinoma     HB                  SNPscan             1039/1674      544     397        98    1485   593    870    672   132   2412   936    0.888
  Zhou                2016   China     Asian            ESCC                                        PB                  PCR-LDR             584/585        325     226        33    876    292    296    238   51    830    340    0.749
  *PD-L1* rs4143815                                                                                                                                        GG      CG         CC    G      C      GG     CG    CC    G      C      
  Catalano            2018   Czech     Caucasian        Colon cancer                                HB                  TaqMan              824/1103       388     345        91    1121   527    514    467   122   1495   711    0.306
  Catalano            2018   Czech     Caucasian        Rectal cancer                               HB                  TaqMan              371/1103       167     162        42    496    246    514    467   122   1495   711    0.306
  Du                  2017   China     Asian            NSCLC                                       HB                  sequencing          320/199        52      145        123   249    391    40     80    79    160    238    0.021
  Tan                 2018   China     Asian            Ovarian cancer                              PB                  PCR-RFLP            164/170        51      82         31    184    144    38     78    54    154    186    0.334
  Tao                 2017   China     Asian            Gastric cancer                              HB                  Sequencing          346/500        123     153        70    399    293    117    223   160   457    543    0.023
  Wang                2013   China     Asian            Gastric cancer                              HB                  sequencing          205/393        88      72         45    248    162    70     188   135   328    458    0.746
  Xie                 2018   China     Asian            HCC                                         HB                  sequencing          225/200        74      101        50    249    201    31     104   65    166    234    0.316
  Zhou                2017   China     Asian            ESCC                                        PB                  PCR-LDR             575/577        87      277        211   451    699    85     289   203   459    695    0.275
  PD-L1 rs2890658                                                                                                                                          AA      AC         CC    A      C      AA     AC    CC    A      C      
  Chen                2014   China     Asian            NSCLC                                       HB                  PCR-RFLP            293/293        242     48         3     532    54     266    26    1     558    28     0.671
  Cheng               2015   China     Asian            NSCLC                                       HB                  PCR-RFLP            288/300        233     51         4     517    59     269    30    1     568    32     0.867
  Ma                  2015   China     Asian            lung cancer                                 PB                  PCR-RFLP            528/600        416     106        6     938    118    512    84    4     1108   92     0.785
  Xie                 2018   China     Asian            HCC                                         HB                  sequencing          225/200        170     49         6     389    61     139    55    6     333    67     0.844
  Zhou                2017   China     Asian            ESCC                                        PB                  PCR-LDR             575/577        18      161        396   197    953    15     144   418   174    980    0.541

List of Abbreviations: HCC: Hepatocellular carcinoma; PB: Population-based; HB: Hospital-based; ESCC: Esophageal squamous cell carcinoma; LDR: Ligase Detection Reaction; NSCLC: non-small cell lung cancer; PCR-RFLP: PCR-Restriction fragment length polymorphism; HWE: Hardy-Weinberg equilibrium; MassARRAY^®^System: Nonfluorescent detection platform utilizing mass spectrometry to accurately measure PCR-derived amplicons.
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###### 

The pooled ORs and 95% CIs for the association between *PD-1* and *PD-L1* polymorphisms and cancer susceptibility.

  Polymorphism        *n*   Genetic Model   Association Test    Heterogeneity Test   Publication Bias Test                                    
  ------------------- ----- --------------- ------------------- -------------------- ----------------------- ------- ---- ----------- ------- -------
  *PD-1* rs2227981    16    CT vs. CC       1.11 (0.93--1.33)   1.16                 0.25                    61.22   75   \<0.00001   0.032   0.031
                            TT vs. CC       0.86 (0.72--1.04)   1.51                 0.13                    27.39   45   0.03        0.034   0.024
                            CT+TT vs. CC    1.05 (0.89--1.24)   0.64                 0.52                    58.58   74   \<0.00001   0.019   0.005
                            TT vs. CT+CC    0.82 (0.68--0.99)   2.04                 0.04                    31.12   52   0.008       0.155   0.150
                            T vs. C         0.98 (0.87--1.09)   0.43                 0.66                    51.48   71   \<0.00001   0.020   0.012
  *PD-1* rs2227982    11    CT vs. CC       1.01 (0.85--1.19)   0.09                 0.930                   24.53   59   0.006       0.359   0.186
                            TT vs. CC       1.05 (0.87--1.26)   0.51                 0.611                   17.10   47   0.050       0.288   0.180
                            CT+TT vs. CC    1.02 (0.86--1.20)   0.22                 0.829                   26.49   62   0.003       0.469   0.484
                            TT vs. CT+CC    1.00 (0.90--1.10)   0.04                 0.97                    7.52    0    0.581       0.184   0.211
                            T vs. C         1.02 (0.92--1.12)   0.38                 0.707                   20.50   51   0.025       0.927   0.715
  *PD-1* rs11568821   9     AG vs. GG       0.79 (0.67--0.94)   2.73                 0.006                   3.89    0    0.87        0.499   0.409
                            AA vs. GG       1.01 (0.47--2.14)   0.01                 0.99                    13.19   47   0.07        0.015   0.091
                            AG+AA vs. GG    0.82 (0.70--0.96)   2.42                 0.020                   11.30   29   0.19        0.613   0.835
                            AA vs. AG+GG    1.07 (0.54--2.13)   0.19                 0.846                   11.79   41   0.11        0.010   0.095
                            A vs. G         0.88 (0.68--1.15)   0.92                 0.36                    24.39   67   0.002       0.822   0.835
  *PD-1* rs7421861    7     CT vs. TT       1.16 (1.02--1.33)   2.20                 0.03                    0.01    46   0.09        0.215   0.881
                            CC vs. TT       1.00 (0.79--1.28)   0.03                 0.98                    4.76    0    0.57        0.116   0.881
                            CT+CC vs. TT    1.14 (0.99--1.31)   1.81                 0.07                    12.93   54   0.04        0.196   0.453
                            CC vs. CT+TT    0.96 (0.75--1.22)   0.37                 0.71                    3.49    0    0.75        0.101   0.652
                            C vs. T         1.09 (0.97--1.23)   1.42                 0.16                    13.02   54   0.04        0.200   0.652
  *PD-1* rs36084323   7     AG vs. GG       0.92 (0.71--1.20)   0.60                 0.55                    27.83   78   0.0001      0.042   0.051
                            AA vs. GG       1.08 (0.77--1.52)   0.45                 0.66                    28.21   79   0.0001      0.079   0.188
                            AG+AA vs. GG    0.88 (0.64--1.21)   0.79                 0.43                    47.46   87   \<0.00001   0.081   0.293
                            AA vs. AG+GG    1.06 (0.83--1.36)   0.46                 0.64                    22.86   74   0.0008      0.137   0.348
                            A vs. G         0.89 (0.70--1.14)   0.92                 0.36                    66.01   91   \<0.00001   0.160   0.453
  *PD-1* rs10204525   6     AG vs. AA       0.94 (0.80--1.10)   0.76                 0.45                    13.13   62   0.02        0.640   0.851
                            GG vs. AA       0.76 (0.53--1.09)   1.48                 0.14                    19.40   74   0.002       0.031   0.091
                            AG+GG vs. AA    0.90 (0.75--1.08)   1.10                 0.27                    18.41   73   0.002       0.399   0.188
                            GG vs. AG+AA    0.78 (0.57--1.09)   1.46                 0.14                    16.64   70   0.005       0.020   0.039
                            G vs. A         0.89 (0.76--1.05)   1.38                 0.17                    23.71   79   0.0002      0.172   0.091
  *PD-L1* rs4143815   8     CG vs. GG       0.75 (0.55--1.01)   1.89                 0.06                    43.76   84   \<0.0001    0.230   0.322
                            CC vs. GG       0.62 (0.41--0.94)   2.28                 0.02                    52.19   87   \<0.00001   0.188   0.138
                            CG+CC vs. GG    0.70 (0.50--0.97)   2.15                 0.03                    43.20   84   \<0.00001   0.184   0.138
                            CC vs. CG+GG    0.76 (0.60--0.96)   2.30                 0.02                    25.19   72   0.0007      0.070   0.138
                            C vs. G         0.78 (0.63--0.96)   2.33                 0.02                    61.68   89   \<0.00001   0.100   0.138
  *PD-L1* rs2890658   5     AC vs. AA       1.36 (0.92--2.01)   1.53                 0.13                    13.83   71   0.008       0.757   0.624
                            CC vs. AA       1.12 (0.68--1.84)   0.45                 0.65                    4.31    7    0.37        0.032   0.050
                            AC+CC vs. AA    1.35 (0.89--2.04)   1.43                 0.15                    16.24   75   0.003       0.736   1.000
                            CC vs. AC+AA    0.90 (0.71--1.15)   0.83                 0.41                    4.25    6    0.37        0.041   0.050
                            C vs. A         1.30 (0.88--1.91)   1.32                 0.19                    25.96   85   \<0.0001    0.248   0.142
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###### 

Stratified analysis of *PD-1* and *PD-L1* polymorphisms with cancer susceptibility.

  Variable                  No.   CT vs. CC             TT vs. CC   CT+TT vs. CC          TT vs. CT+CC   T vs. C                                                                     
  ------------------------- ----- --------------------- ----------- --------------------- -------------- ------------------- ------- ------------------- ------- ------------------- -------
  ***PD-1*** rs2227981            OR (95% CI)           *p*         OR (95% CI)           *p*            OR (95% CI)         *p*     OR (95% CI)         *p*     OR (95% CI)         *p*
  Asian                     14    1.16 (0.94--1.43)     0.173       0.89 (0.71--1.12)     0.312          1.09 (0.90--1.32)   0.393   0.83 (0.66--1.04)   0.106   1.00 (0.87--1.14)   0.953
  Population-based          13    1.12 (0.91--1.39)     0.276       0.88 (0.70--1.07)     0.175          1.06 (0.87--1.28)   0.571   0.81 (0.66--1.01)   0.060   0.97 (0.85--1.10)   0.611
  Hospital-based            3     1.06 (0.72--1.61)     0.714       0.91 (0.53--1.59)     0.749          1.04 (0.68--1.57)   0.873   0.85 (0.57--1.26)   0.421   1.03 (0.76--1.41)   0.839
  Gastrointestinal cancer   3     1.13 (0.73--1.76)     0.588       0.68 (0.56--0.84)     0.000          0.95 (0.71--1.27)   0.713   0.60 (0.40--0.89)   0.011   0.83 (0.75--0.91)   0.000
  Lung cancer               3     0.91 (0.76--1.10)     0.324       0.65 (0.44--0.97)     0.030          0.84 (0.71--0.99)   0.043   0.69 (0.45--1.04)   0.079   0.83 (0.72--0.95)   0.009
  Breast cancer             2     0.78 (0.56--1.08)     0.136       0.76 (0.53--1.10)     0.147          0.80 (0.59--1.01)   0.058   0.83 (0.59--1.17)   0.291   0.82 (0.70--0.96)   0.012
  ***PD-1*** rs2227982            CT vs. CC             TT vs. CC   CT+TT vs. CC          TT vs. CT+CC   T vs. C                                                                     
  Asian                     10    1.02 (0.85--1.21)     0.845       1.04 (0.87--1.26)     0.655          1.02 (0.86--1.22)   0.790   1.00 (0.90--1.10)   0.921   1.02 (0.92--1.12)   0.708
  Population-based          8     0.91 (0.73--1.12)     0.363       0.99 (0.73--1.33)     0.934          0.93 (0.741.16)     0.507   0.99 (0.83--1.17)   0.734   0.98 (0.85--1.14)   0.818
  Hospital-based            3     1.22 (1.06--1.40)     0.006       1.16 (0.99--1.37)     0.067          1.20 (1.05--1.37)   0.008   1.02 (0.89--1.16)   0.806   1.08 (0.99--1.17)   0.077
  Gastrointestinal cancer   4     1.18 (1.04--1.34)     0.011       1.12 (0.97--1.29)     0.133          1.16 (1.03--1.30)   0.017   1.00 (0.89--1.12)   0.989   1.06 (0.98--1.34)   0.146
  Breast cancer             2     0.73 (0.59--0.90)     0.004       0.73 (0.57--0.93)     0.010          0.73 (0.60--0.89)   0.002   0.89 (0.74--1.09)   0.257   0.85 (0.76--0.96)   0.010
  ***PD-1*** rs7421861            CT vs. TT             CC vs. TT   CT+CC vs. TT          CC vs. CT+TT   C vs. T                                                                     
  Hospital-based            5     1.89 (1.01--1.40)     0.042       1.05 (0.79--1.39)     0.745          1.16 (0.98--1.38)   0.096   0.99 (0.74--1.31)   0.916   1.11 (0.95--1.29)   0.192
  Population-based          2     1.09 (0.86--1.39)     0.478       0.89 (0.56--1.43)     0.630          1.07 (0.84--1.37)   0.565   0.88 (0.55--1.40)   0.586   1.04 (0.85--1.28)   0.692
  Gastrointestinal cancer   5     1.19 (1.01--1.40)     0.042       1.05 (0.79--1.39)     0.745          1.16 (0.97--1.38)   0.096   1.00 (0.75--1.32)   0.979   1.11 (0.95--1.29)   0.192
  Breast cancer             2     1.09 (0.86--1.39)     0.478       0.89 (0.56--1.43)     0.630          1.07 (0.84--1.37)   0.565   0.88 (0.55--1.40)   0.586   1.04 (0.85 (1.28)   0.692
  ***PD-1*** rs11568821           AG vs. GG             AA vs. GG   AG+AA vs. GG          AA vs. AG+GG   A vs. G                                                                     
  Population-based          7     0.80 (0.66--0.97)     0.020       1.02 (0.43--2.42)     0.968          0.86 (0.65--1.14)   0.288   1.09 (0.50--2.38)   0.833   0.92 (0.78--1.08)   0.294
  Hospital-based            2     0.77 (0.55--1.10)     0.150       0.76 (0.20--2.90)     0.688          0.77 (0.55--1.09)   0.140   0.76 (0.21--3.02)   0.736   0.80 (0.58--1.09)   0.152
  ***PD-1*** rs36084323           AG vs. GG             AA vs. GG   AG+AA vs. GG          AA vs. AG+GG   A vs. G                                                                     
  Asian                     6     0.95 (0.71--1.25)     0.691       1.05 (0.75--1.47)     0.769          0.86 (0.61--1.23)   0.412   1.05 (0.82--1.33)   0.715   0.86 (0.67--1.12)   0.259
  Population-based          5     0.78 (0.50--1.21)     0.268       0.88 (0.47--1.63)     0.674          0.71 (0.42--1.22)   0.219   0.94 (0.61--1.45)   0.767   0.74 (0.49--1.12)   0.152
  Hospital--based           2     1.13 (0.97--1.32)     0.127       1.26 (1.00--1.59)     0.052          1.17 (1.01--1.35)   0.042   1.93 (0.87--1.64)   0.277   1.12 (1.00--1.26)   0.05
  ***PD-1*** rs10204525           AG vs. AA             GG vs. AA   AG+GG vs. AA          GG vs. AG+AA   G vs. A                                                                     
  Gastrointestinal cancer   5     0.90 (0.76--1.07)     0.227       0.63 (0.45--1.04)     0.078          0.86 (0.70--1.04)   0.121   0.72 (0.48--1.06)   0.096   0.85 (0.71--1.02)   0.077
  Population-based          3     0.85 (0.58--1.23)     0.382       0.60 (0.28--1.32)     0.203          0.80 (0.52--1.32)   0.312   0.65 (0.35--1.23)   0.186   0.80 (0.55--1.17)   0.246
  Hospital-based            3     0.99 (0.88--1.22)     0.908       0.90 (0.63--1.29)     0.568          0.99 (0.88--1.11)   0.831   0.89 (0.60--1.32)   0.560   0.99 (0.90--1.08)   0.767
  ***PD-L1*** rs4143815           CG vs. GG             CC vs. GG   CG+CC vs. GG          CC vs. CG+GG   C vs. G                                                                     
  Gastrointestinal cancer   6     0.68 (0.48--0.97)     0.032       0.59 (0.37--0.96)     0.033          0.64 (0.43--0.95)   0.028   0.77 (0.58--1.02)   0.064   0.76 (0.59--0.98)   0.034
  Hospital-based            6     0.71 (0.48--1.05)     0.087       0.60 (0.36--1.00)     0.051          0.67 (0.44--1.02)   0.059   0.75 (0.58--0.97)   0.030   0.76 (0.58--0.99)   0.043
  Population-based          2     0.89 (0.68--1.18)     0.414       0.68 (0.29--1.59)     0.378          0.82 (0.55--1.23)   0.332   0.76 (0.36--1.59)   0.460   0.83 (0.53--1.30)   0.413
  ***PD-L1*** rs2890658           AC vs. AA             CC vs. AA   AC+CC vs. AA          CC vs. AC+AA   C vs. A                                                                     
  Lung cancer               3     1.74 (1.37--2.19)     0.000       2.48 (0.92--6.69)     0.072          1.77 (1.41--2.23)   0.000   2.29 (0.85--6.16)   0.101   1.72 (1.39--2.13)   0.000
  Gastrointestinal cancer   2     4.34 (0.13--148.07)   0.415       4.43 (0.17--112.70)   0.368          0.76 (0.53--1.10)   0.141   0.84 (0.66--1.08)   0.179   0.84 (0.69--1.01)   0.070
  Hospital-based            3     1.42 (0.72--2.96)     0.317       1.61 (0.52--4.98)     0.409          1.45 (0.72--2.92)   0.296   1.45 (0.57--3.73)   0.439   1.46 (0.75--2.82)   0.266
  Population-based          2     6.30 (0.39--103.18)   0.197       6.85 (0.60--78.36)    0.122          1.23 (0.67--2.26)   0.503   0.90 (0.56--1.37)   0.636   1.13 (0.65--1.97)   0.661
